Cervical Cancer
Conditions
Keywords
Cervical cancer, neutrophil to lymphocyte ratio (NLR), lymphocyte to monocyte ratio (LMR), platelet to lymphocyte ratio (PLR)
Brief summary
Although significant advances in screening and treatment , cervical cancer is the fifth most common female cancer in Europe. Major prognostic factors for oncological outcome are used to categorise patients at high, intermediate and low risk groups and to define the type of radical hysterectomy according Querleu-Morrow classification. The goal of this prospective observational study is to evaluate the association between several inflammatory markers and risk groups according European guidelines in women with cervical cancer Human Papillomavirus (HPV)-associated, in order to optimize the treatment.
Detailed description
European guidelines have proposed a risk stratification of patients basing on oncological risk. The type of radical hysterectomy (extent of parametrial resection and type according Querleu-Morrow classification) should be based upon the presence of prognostic risk factors.Major prognostic factors for oncological outcome as tumour size, maximum stromal invasion, Lymphovascular space invasion (LVSI) are used to categorise patients at high, intermediate and low risk for treatment failure. The investigators want to identify additional parameters to better define risk profiles. Systemic inflammation indices such as neutrophil to lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and lymphocyte to monocyte ratio (LMR) have shown prognostic value in solid tumors and several inflammatory conditions. Therefore, the primary endpoint of the present study is to assess the role of systemic inflammatory indices and risk groups stratification in patients with early cervical cancer.
Interventions
DIAGNOSTIC_TESTVenous blood sample
Blood chemistry tests: neutrophil;lymphocyte; monocyte; platelet counts
PROCEDUREbiopsy
histopathology findings
Sponsors
University of Campania Luigi Vanvitelli
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* At least 18-year-old patients. * Patients histologically diagnosed with cervical cancer (squamous cell carcinoma or adenocarcinoma HPV- associated) * Patients with (2018 FIGO) stage ≤ IB2 (Early Cervical Cancer) * Patients undergoing full-body CT-scan 30 days before enrollment.
Exclusion criteria
* Patients unfit to plead * Patients with chronic inflammatory diseases (IBDs; rheumatic conditions) * Synchronous tumors or cancer diagnosis in the previous 3 years * Patients undergoing steroid therapy in the last 30 days prior to recruitment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Grading | 30 days after surgery | Anatomic pathology report of cell anaplasia in the sampled tumor |
| Staging | 30 days after surgery | Anatomic pathology report of extent to which the cancer has spread |
| Lymphovascular space invasion | 30 days after surgery | Prognostic factor in cervical cancer |
| Histotype | 30 days after surgery | Anatomic pathology report of tissue types of cancer |
| Tumor size | 30 days after surgery | centimeters |
| Neutrophil-Lymphocyte Ratio (NLR) | 1 day previous surgery | an absolute value obtained from the ratio of neutrophils to lymphocytes |
| Platelet-lymphocyte ratio(PLR) | 1 day previous surgery | an absolute value obtained from the ratio of platelets to lymphocytes |
| Lymphocyte-monocyte Ratio (LMR) | 1 day previous surgery | an absolute value obtained from the ratio of lymphocytes to monocytes |
Countries
Italy
Contacts
Primary ContactCarlo Ronsini, MD
Outcome results
None listed